Pipeline Watch
30 October 2009
This week's quieter Pipeline Watch table records one first launch and two first approvals for new products. While the US FDA is still mulling over how to implement class-wide risk evaluation and mitigation strategy (REMS) for long-acting opioids, Meda has launched its product Onsolis (fentanyl buccal...
Please Login to read the full article.
30 October 2009
This week's quieter Pipeline Watch table records one first launch and two first approvals for new products. While the US FDA is still mulling over how to implement class-wide risk evaluation and mitigation strategy (REMS) for long-acting opioids, Meda has launched its product Onsolis (fentanyl buccal...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US Capitol Capsule: FDA's CDER ends 2011 with 30 new drugs and biologics
- BioDelivery's cancer pain drug Onsolis set for launch in Canada
- BioDelivery clinches $30M up front from Endo in deal for PhIII buccal mucosa chronic pain treatment
- BioDelivery hopes modified REMS will put cancer pain drug Onsolis in retail pharmacies
COMMENT
Other Informa Comment
EVENTS
09 February 2012
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
